Raia Drogasil (RADLY) Stock Price, News & Analysis

Company Overview

Raia Drogasil, now known as RD Saúde, is a Brazilian health and pharmacy retail company formed in 2011 through the merger of Droga Raia and Drogasil. It operates pharmacy stores under the Raia and Drogasil brands.

The company sells prescription and over-the-counter medicines, personal care and beauty products, and other health and wellness goods. It serves customers across Brazil through its retail locations and digital channels, including online ordering and delivery.

In addition to pharmacy retail, RD Saúde provides health-related services through its stores and digital platforms. Its business combines the legacy operations of two long-established Brazilian pharmacy chains.

Key Stats

• Today's Range: $2.56 to $2.60
• 50-Day Range: $2.57 to $4.39
• 52-Week Range: $2.56 to $5.34
• Volume: 953 shs
• Average Volume: 23,027 shs
• Market Capitalization: $3.41 billion
• P/E Ratio: 17.31
• Dividend Yield: 1.54%
• Price Target: $5.20
• Consensus Rating: Moderate Buy

Raia Drogasil Stock Analysis - MarketRank™

Raia Drogasil scored higher than 94% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Raia Drogasil has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Upside Potential

Raia Drogasil has a consensus price target of $5.20, representing about 100.3% upside from its current price of $2.60.

Amount of Analyst Coverage

Raia Drogasil has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 29.41%

Earnings Growth

Earnings for Raia Drogasil are expected to grow by 29.41% in the coming year, from $0.17 to $0.22 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Raia Drogasil is 17.31, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.41.

Price to Earnings Ratio vs. Sector

The P/E ratio of Raia Drogasil is 17.31, which means that it is trading at a less expensive P/E ratio than the Consumer Staples sector average P/E ratio of about 24.87.

Price to Book Value per Share Ratio

Raia Drogasil has a P/B Ratio of 2.60. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Raia Drogasil has been sold short.

Short Interest Ratio / Days to Cover

Raia Drogasil has a short interest ratio ("days to cover") of 0.17, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Raia Drogasil has recently increased by 826.48%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Raia Drogasil pays a meaningful dividend of 1.42%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Raia Drogasil does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Raia Drogasil is 26.67%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Raia Drogasil will have a dividend payout ratio of 18.18% next year. This indicates that Raia Drogasil will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.16

News Sentiment

Raia Drogasil has a news sentiment score of 0.16. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Consumer Staples companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Raia Drogasil this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Raia Drogasil insiders have not sold or bought any company stock.

Percentage Held by Institutions

Raia Drogasil has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 11/03/2026
• Today: 11/14/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Consumer Staples
• Industry: Consumer Staples Distribution & Retail
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:RADLY
• CIK: N/A
• Web: rdsaude.com.br
• Phone: 551137695678
• Fax: N/A
• Employees: 69,900
• Year Founded: 2011

Price Target and Rating

• Average Price Target for Raia Drogasil: $5.20
• High Price Target: $5.20
• Low Price Target: $5.20
• Potential Upside/Downside: +100.3%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.15
• Trailing P/E Ratio: 17.31
• Forward P/E Ratio: 11.80
• P/E Growth: N/A
• Net Income: $232.27 million
• Net Margins: 2.89%
• Pretax Margin: 3.33%
• Return on Equity: 20.61%
• Return on Assets: 6.02%

Debt

• Debt-to-Equity Ratio: 0.99
• Current Ratio: 1.41
• Quick Ratio: 0.58

Sales & Book Value

• Annual Sales: $7.92 billion
• Price / Sales: 0.43
• Cash Flow: $0.47 per share
• Price / Cash Flow: 5.51
• Book Value: $1.00 per share
• Price / Book: 2.60

Miscellaneous

• Outstanding Shares: 1,315,250,000
• Free Float: N/A
• Market Cap: $3.41 billion
• Optionable: Not Optionable
• Beta: N/A